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Abstract
Background—Little is known about risk factors for persistent high-risk HPV (hrHPV) infection 
in low-income settings, and prior research has not quantified the relative duration of hrHPV 
infections stratified by risk factors. We compared the duration of hrHPV infection among female 
sex workers (FSW) by exposure to sexually transmitted infections (STIs), using a highly-sensitive 
biomarker assay.
Methods—From 2009–2011, 350 FSW enrolled in this longitudinal study. Every three months, 
sociodemographic and sexual behavior data were collected via questionnaire, and APTIMA assays 
were used to detect the rRNA of Chlamydia trachomatis (CT), Neisseria gonorrhea (GC), 
Trichomonas vaginalis (TV), Mycoplasma genitalium (MG), and mRNA of the E6/E7 
oncoproteins expressed by hrHPV. Among 173 FSW who were infected with hrHPV during the 
observation period, accelerated failure time models estimated time ratios (TR) for duration of 
hrHPV infection, comparing FSW infected with STIs at baseline to STI-uninfected FSW.
Results—Median follow-up time was 26.2 months (IQR: 18.8 – 27.5). The median duration of 
hrHPV infection among all FSW was 9.3 months (95% CI: 9.3, 11.5). The duration of hrHPV 
infection among FSW infected with CT at baseline was greater than that among FSW who were 
uninfected (adjusted TR: 1.7, 95% CI: 1.2, 2.6). Among FSW who were co-infected with hrHPV 
and CT at baseline, the adjusted TR was 3.4 (95% CI: 2.5, 5.4) compared to FSW infected with 
hrHPV only. No other STI was associated with hrHPV duration.
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Conclusion—Recent or concurrent CT infection was associated with prolonged hrHPV infection 
among a cohort of Nairobi FSW. Management of CT could reduce risk for hrHPV persistence.
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INTRODUCTION
Over 100 types of human papillomavirus (HPV) have been identified, at least 13 of which 
are high-risk types that cause high-grade pre-cancerous squamous intraepithelial lesions 
(HSIL) and subsequent invasive cervical cancer (ICC).1 While most HPV infections resolve 
on their own within one year, certain high-risk HPV (hrHPV) types are more likely to persist 
for longer, such as types 16, 33, and 31.2 Thus, persistent hrHPV infection is the most 
important risk factor for the development of ICC.3 There is currently no standard treatment 
for hrHPV viral infections, and resource-limited settings often lack the health infrastructure 
to adequately screen for and treat HSIL and ICC. In Kenya, the Pap test is the primary form 
of cervical cancer screening, but is generally only available in urban areas and is subject to 
long delays between screening and obtaining results. Visual inspection with acetic acid is 
available in resource-limited settings, but outpatient treatment services (e.g. cryotherapy and 
loop electrosurgical excision procedure) are largely unavailable throughout the country.4 In 
the absence of a national HPV vaccination strategy, identifying risk factors for persistent 
hrHPV can improve resource-efficient cervical cancer prevention.
Sexually transmitted infections (STIs) have been associated with longer hrHPV persistence 
in previous studies. Two studies of adolescent women in the United States showed 
significant positive associations between Chlamydia trachomatis and Trichomonas vaginalis 
and hrHPV persistence,5,6 and two studies of adult women in Sweden and China showed 
that Chlamydia trachomatis and bacterial vaginosis, respectively, were significant risk 
factors for hrHPV persistence.7,8 In light of these findings, management of STIs is a 
potential prevention strategy to reduce hrHPV persistence among women.
While this strategy might be effective among groups at relatively lower risk for hrHPV, few 
studies have explored the relationship between STIs and hrHPV persistence in high-risk 
groups, including female sex workers. Female sex workers (FSW) are at increased risk for 
acquiring hrHPV due to their higher number of sexual partners and frequency of sex acts. 
Prevalence studies among FSW indicate high hrHPV burden, sometimes affecting half or 
more of respondents.9,10 In spite of being at high risk, only one published study has 
explored risk factors for hrHPV persistence among FSW11, and to our knowledge none have 
focused on sub-Saharan Africa. In addition, few risk factor analyses have statistically 
quantified persistence of hrHPV infections using continuous time in number of days or 
months, rather than a number of time intervals.12,13 Further, fully parametric methods for 
longitudinal data have not yet been implemented in the published literature to measure 
relative time to clearance of hrHPV infection, comparing individuals with and without given 
risk factors.
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We present here results of a study to quantify the relative duration of hrHPV infection 
among FSW in Nairobi, Kenya with history of laboratory-confirmed infection with one or 
more of four STIs - Chlamydia trachomatis (CT), Neisseria gonorrhea (GC), Trichomonas 




Study procedures and data collection took place in the Korogocho clinic in Nairobi, Kenya. 
From August 2009 to March 2011, FSW attending the Korogocho clinic were invited to 
participate in the study during “baraza” public meetings, as previously described.14 Women 
who had received hysterectomies or were in the second trimester of pregnancy or later were 
considered ineligible for the study. A total of 425 FSW ages 18–49 were approached to 
participate, and 350 provided written informed consent to enroll into the study. At screening, 
participants responded to a questionnaire, administered by a trained study nurse or 
counselor, to collect sociodemographic, reproductive, and sexual behavior data.
Sample collection and laboratory analyses
During a pelvic examination, a physician collected one cervical sample from each woman 
using a Cervex-Brush (Rovers Medical Devices, The Netherlands), which was then swirled 
in the PreservCyt medium (Hologic Corporation, Marlborough, MA) and later discarded. 
The physician then collected a second cervical sample for conventional Pap smear. Cervical 
samples were stored in liquid-based APTIMA assay media at the Korogocho clinic, and 
were transported the same day to the University of Nairobi research laboratory, which is 
approximately 15 kilometers from the clinical site. Cytological smears were evaluated at the 
University of Nairobi and classified according to the 2001 Bethesda System for cervical 
cytology. All smears were independently read by two cytopathologists blinded to hrHPV 
and STI testing results. For discrepant cases, the final diagnosis was made based on the 
consensus of the reviewing cytopathologists. Samples were processed the same day as 
collection for HIV testing, and were stored at 4° Celsius until shipment to the Hologic 
Corporation (formerly Gen-Probe) testing laboratory in San Diego, CA, USA for hrHPV and 
STI testing.
hrHPV and STI testing
Laboratory testing for hrHPV was conducted using the APTIMA HPV Assay (AHPV; 
Hologic Corporation, San Diego) which qualitatively detects E6/E7 mRNA of 14 hrHPV 
types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68).15 Positive hrHPV samples 
were genotyped at the baseline visit (i.e. the first study visit for all participants) using the 
APTIMA HPV 16 18/45 Genotype Assay to determine the presence of hrHPV types 16 and 
18/45; the assay does not detect any additional types and does not distinguish between types 
18 and 45. hrHPV assay results were considered positive based on a signal-to-cutoff ratio of 
0.5.15
Vielot et al. Page 3













Infection statuses for CT and GC were obtained with the APTIMA Combo 2 assay; for TV 
with the APTIMA TV assay; and for MG with the APTIMA research use only assay, using 
the same target capture, transcription-mediated amplification and hybridization steps as 
AHPV detection. All assays were performed according to the manufacturer’s instructions, 
without knowledge of the Pap smear or other study results.
Measures
The study period comprised nine total clinic visits at approximately three-month intervals, 
with analysis beginning at a participant’s first positive hrHPV test. Participants who entered 
the study with an existing hrHPV diagnosis were considered prevalent infections, whereas 
participants who were not infected until later in the study were considered incident hrHPV 
infections. Persistence of a hrHPV infection was quantified based on the number of 
consecutive positive hrHPV diagnoses at three-month study intervals. We counted the 
number of intervals from the first positive hrHPV test until at least one subsequent hrHPV 
test was negative, or until the participant was lost to follow-up. We computed a minimum 
and maximum duration of infection for each participant, accounting for unobserved time 
between clinic visits during which hrHPV infections could have occurred or cleared 
(Statistical Appendix). The difference in the clinic visit dates between the end and start of 
each interval was used to compute the minimum and maximum duration.
Only the first instance of continuous hrHPV infection per participant was considered for this 
analysis. Consecutive positive hrHPV tests were assumed to represent a persistent infection, 
as hrHPV type data were only available for the baseline samples. Duration of hrHPV 
infection was right censored at the time of last positive test for participants who a) missed 
two or more consecutive study visits following a positive hrHPV diagnosis (lost to follow 
up), or b) were still positive at the last study visit. If only a single visit was missed the 
missing hrHPV status was imputed using the last observed value for hrHPV status.
Statistical Analysis
Nonparametric survival curves were generated using the expectation-maximization iterative 
convex minorant (EM-ICM) algorithm, an extension of the standard Kaplan-Meier estimator 
for interval-censored data.16 The generalized log-rank test statistic was used to compare the 
median duration of hrHPV infection between strata of STI and HIV infection status, cervical 
cytology, and sexual risk factors16. Parametric accelerated failure time (AFT) models were 
employed to estimate crude and adjusted time ratios (TR) among FSW who experienced 
hrHPV infection at any time during the observation period. The generalized gamma 
distribution was assumed to be the best fit. All analyses were performed using SAS version 
9.4 (Cary, North Carolina).17
RESULTS
Participant health status and behavioral risk factors
Of the original 350 participants, 173 (49.4%) had a positive hrHPV result at least once over 
the course of the study, of which 103 (59.5%) had a prevalent hrHPV infection at baseline, 
and 70 (40.5%) acquired a hrHPV infection during follow-up. These 173 participants 
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comprised the final study sample. The median age of the participants in the sample was 27 
years (range: 19 – 48). Over one-third (37.6%) of the participants reported participating in 
sex work for more than five years. Less than one-fourth (24.3%) of the participants reported 
using condoms consistently with their clients. The median number of clients per week was 
12 (Appendix 2). The prevalence of each STI at baseline was as follows: CT – 6.4%; GC – 
3.5%; MG – 16.8%; TV – 9.3% and HIV – 29.5% (Appendix 2).
Median follow-up time was 25.5 months (IQR: 8.5 – 27.4) among participants with 
prevalent hrHPV infections, and 26.6 months (IQR: 25.3 – 28.2) among participants with 
incident hrHPV infections. All participants had at least one missing visit of the total nine 
visits, requiring imputation of at least one missing hrHPV status. Among all infections, 99 
(57.2%) experienced clearance of a hrHPV infection over follow-up, 46 were lost to follow 
up (26.6%), and 28 (16.2%) remained positive and were administratively censored after the 
ninth visit. Thirteen (12.6%) of the participants infected with hrHPV at baseline were 
infected with type 18/45; 14 (13.6%) were infected with type 16; 2 (1.9%) were infected 
with both 18/45 and 16; and 74 (71.8%) were infected with some other hrHPV type.
The median duration of hrHPV infection among all cases was 9.3 months (95% CI: 9.3, 
11.5), with a range from 1.8 – 31.3 months (Table 1). Among those infected with type 16 at 
baseline, the median duration of infection was 23.6 months (95% CI: 5.7, ∞), and the 
median duration among those infected with type 18/45 was 11.5 months (95% CI: 5.2, 11.5); 
however this difference did not reach significance at the 0.05 alpha level (p=0.07). Median 
duration was significantly longer among participants infected with CT at baseline compared 
to those who were uninfected (19.4 months vs. 9.3 months, p=0.05) (Table 1, Figure 1a). 
FSW who reported 12 or more clients per week on average had a significantly longer 
median duration than those who had fewer than 12 (11.2 vs. 9.3, p=0.03). An increasing 
trend in median duration was also observed by levels of cervical cytology results 
(Normal=7.9; atypical squamous cells of undetermined significance (ASCUS), atypical 
glandular cells of undetermined significance (AGUS), or low-grade squamous intraepithelial 
lesions (LSIL)=11.5; HSIL=17.3, p=0.06). No significant differences were observed based 
on other STI infections, HIV status, age group, or sexual risk behaviors. The median 
duration of hrHPV infection was longer among participants infected with GC compared to 
those who were uninfected, but this finding did not reach statistical significance due in part 
to a small number of positive GC results (N=6).
Relative time to clearance of hrHPV infection
The median duration of hrHPV infection among participants infected with CT at baseline 
was almost twice that among participants who were uninfected at baseline (TR: 1.9, 95% CI: 
1.1, 3.1) (Table 2). The positive association between CT and hrHPV persistence was slightly 
attenuated after adjusting for age and baseline HIV status, but remained statistically 
significant (TR: 1.7, 95% CI: 1.2, 2.6). Among participants who were infected with hrHPV 
at baseline, the duration of hrHPV infections was over three times as long (adjusted TR: 3.4, 
95% CI: 2.4, 4.8) among participants who were co-infected with CT compared to those 
infected with hrHPV only (Table 3). No association was observed between CT at baseline 
and the duration of incident hrHPV infections. Restricting to participants with normal 
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cytology, the adjusted TR for the association between CT infection and time to clearance 
was 1.7 (95% CI: 1.1, 2.5). We could not restrict to participants with abnormal cytology due 
to limited sample size. A sensitivity analysis using a stricter definition of hrHPV clearance – 
two consecutive negative tests following a hrHPV infection – found a similar positive 
association between CT infection and hrHPV persistence. The estimate among prevalent 
hrHPV infections was not strongly affected quantitatively, however the estimate among 
incident infections achieved statistical significance in the sensitivity analysis (aTR: 3.7, 95% 
CI: 1.9, 7.1).
After adjusting for age and baseline HIV status, increasing severity of cytological changes 
were associated with longer time to clearance of hrHPV infection. Among FSW with 
ASCUS/AGUS/LSIL, time to clearance was 80% longer compared to FSW with normal 
cytology (adjusted TR: 1.8, 95% CI: 1.5, 2.2). Among FSW with HSIL, the time to 
clearance was twice as long compared to FSW with normal cytology (adjusted TR: 2.1, 95% 
CI: 1.6, 2.7) (Table 2) (Figure 1b–c).
DISCUSSION
Among a cohort of high-risk FSW in Nairobi, we found that women with laboratory-
confirmed CT had a nearly two-fold duration of hrHPV infection. This relationship was not 
observed with respect to any other STI, nor with HIV in contrast with previous findings18. 
Positive associations between CT and HPV persistence was previously shown using 
polymerase chain reaction (PCR) to detect HPV DNA, and PCR, ligase chain reaction, 
strand displacement amplification, and microimmunofluorescence to detect CT DNA.5,6 
However, methodological limitations such as small sample size and self-reported STI 
history may have caused bias in previous works. The current study is the first to diagnose 
hrHPV infection among FSW using mRNA of the E6/E7 oncoproteins, and the first to use 
AFT models to estimate a relative duration of infection with hrHPV with respect to risk 
factors of interest, rather than defining persistence as presence of type-specific hrHPV at 
two consecutive points in time.
We measured the association between CT and hrHPV persistence, given that hrHPV 
persistence is consistently associated with higher risk of histological cervical intraepithelial 
neoplasia grade 2 or higher (CIN2+).3 In contrast to our findings, a case-control study by 
Safaeian, et al found that baseline CT infection was not associated with prevalent or incident 
CIN2+ among women with hrHPV-positivity at baseline, but was positively associated with 
hrHPV acquisition.19 This might indicate that shared sexual risk factors for acquiring CT 
and hrHPV, rather than an effect of CT on hrHPV persistence, explains the associations that 
have been observed between CT and cervical precancer and ICC. However, our findings are 
consistent with prior research on the potential etiological role of cervical inflammation in 
cervical cancer carcinogenesis, independent of hrHPV infection.20,21 One biological 
explanation is that CT infection can lead to severe and chronic cervical inflammation 
through up-regulation of cytokines, proteins that trigger the immune response. In a South 
African study of HIV-infected women, CT was shown to produce greater concentrations 
than GC and TV of pro-inflammatory cytokines, including interleukins (IL), tumor necrosis 
factors (TNF), and macrophage inflammatory proteins (MIP).22 Further, a study of 154 
Vielot et al. Page 6













HPV-infected women from Hawaii found that persistent HPV infection was positively 
associated with elevated levels of MIP-1a and TNF, Type-1 cytokine IL-12, and regulatory 
cytokine IL-10.23 The interaction between these inflammatory processes associated with 
both HPV and CT infections may cause epithelial damage to the cervix, leading to 
prolonged hrHPV infection and increasing the risk for developing precancerous cervical 
lesions.
While we observed an overall positive association between CT infection and hrHPV 
persistence, this association was strengthened when restricting to prevalent hrHPV cases 
(i.e. CT-hrHPV co-infection) and was not observed when restricting to incident hrHPV 
cases. This finding suggests that co-infection with CT is a more salient risk factor for hrHPV 
persistence than recent CT infection. This is a reasonable conclusion, given that all clinic 
attendees who test positive for STIs were treated and any inflammation caused by CT should 
have subsided following treatment. Women were treated for CT infection immediately after 
diagnosis, which typically occurred within a maximum of 1.5 months following the study 
visit, notably reducing the possibility of CT persistence between the three month study 
intervals. Due to a very small number of concurrent CT infections among incident hrHPV 
cases (n=4), we were not able to assess the effect of CT and hrHPV co-infection in this 
subset.
This study has several strengths. We used narrow and multiple follow-up intervals, allowing 
us to identify hrHPV infection and clearance more precisely than was possible in previous 
studies, many of which measured persistence based on the presence of hrHPV at two 
consecutive time points only, and collected data in intervals of six months to several 
years.5,7,8,24–26,13,27–29. Second, while parametric methods, notably logistic regression to 
estimate odds ratios, are popular for evaluating hrHPV persistence, AFT models to estimate 
time ratios had not been implemented to our knowledge in the published literature prior to 
this work. The fully-parametric AFT family of models is preferable to semiparametric 
longitudinal methods like Cox proportional hazards, notably by allowing more precise 
estimation of association measures for interval-censored data. Third, we were able to 
distinguish between prevalent and incident hrHPV infections acquired during the 
observation period. This allowed us to isolate the association of concurrent CT and hrHPV 
infection with hrHPV persistence as compared to the association of recent CT with hrHPV 
persistence. We found that individuals with prevalent and incident hrHPV infections had 
similar levels of behavioral and biological factors (Appendix 2). This finding supported 
combining incident and prevalent infections into a single sample, which has been done in 
previous studies of hrHPV persistence. Sensitivity analysis also showed that loss to follow-
up had a minimal impact on the association between CT infection and hrHPV persistence 
and did not appreciably change the magnitude or interpretations of our findings (data not 
shown). Finally, the APTIMA hrHPV assay is highly sensitive and relatively more specific 
for the detection of HSIL than DNA-based methods. The APTIMA hrHPV assay detects 
HPV type 66, which was reclassified in 2009 by the International Agency for Research on 
Cancer as possibly carcinogenic, rather than carcinogenic.30 However, HPV 66 is still 
included in other HPV tests, including the FDA-approved cobas® test by Roche.31 Any loss 
in the specificity of the test by including this lower-risk type is minor.
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Methodological limitations include a relatively small sample size and substantial loss to 
follow-up (26.6%) over nine visits. Additionally, AFT models do not allow for the analysis 
of time-varying covariates in order to reliably determine the impact of incident, recurrent, or 
unresolved STIs on hrHPV persistence. Finally, because genotype data for hrHPV types 16 
and 18/45 were only available at the baseline visit, it was not possible to define persistence 
as the presence of the same hrHPV type in consecutive visits, as has been done in prior 
studies.5,8,24,25,28,29 Because our follow-up intervals were short, the probability that 
consecutive infections were indeed of the same type is higher. However, this does not rule 
out the possibility of re-infection with the same or another hrHPV type in the space between 
intervals. Given the high rate of new partners in this population, new infections likely did 
occur with some frequency. Additionally, the evidence for type-specific immunity following 
hrHPV infection is not conclusive,32,33 and there is evidence for a latency period of hrHPV 
infection during which it can lay dormant and reactivate in the future.34–36 Still, the 
evidence is strong that repeated positive hrHPV diagnoses is an important risk factor for 
HSIL and ICC, regardless of whether this represents true persistence, reinfection, or 
reactivation of a latent infection. Incidentally, a study of high-risk adolescents in the United 
States found that re-detection of the same hrHPV DNA type by PCR after apparent 
clearance for six months or longer was positively associated with concurrent CT infection by 
PCR at the time of redetection of hrHPV DNA (hazard ratio: 3.14, 95% CI: 1.44, 6.86),37 
lending additional support to a relationship between CT and hrHPV persistence, whether 
overt or latent.
Our findings suggest that improved clinical management of CT may reduce the duration of 
hrHPV infections and risk for cervical precancer. These findings should be interpreted with 
caution, however, given that HPV persistence is an intermediate endpoint on the biological 
pathway between hrHPV infection and ICC risk, and is not equivalent to HSIL per se. 
Further research is needed on the impact of STI treatment on reducing hrHPV persistence 
and incidence of high grade lesions. Such research is feasible given that STI diagnosis and 
treatment can be achieved relatively cheaply and effectively, and is used to reduce 
secondary outcomes such as preterm birth and infertility.
The bivalent and quadrivalent HPV vaccines, which protect against hrHPV types 16 and 18, 
are the optimal preventive measures against hrHPV and cervical cancer, but are not yet 
widely available to the general public in Kenya due to cost and logistical restraints. Even if 
availability and acceptance of the vaccine were high, most FSW in our sample are beyond 
the approved age to receive either vaccine. Without a health care policy that implements 
widespread HPV vaccination of youth, hrHPV will continue to spread through high-risk 
populations in Kenya. Improving detection and treatment of STIs, particularly CT, might 
prove to be another prevention tool to reduce the burden of HSIL and associated ICC in 
resource-limited settings.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Median duration of hrHPV infection in months by baseline health status and sexual risk factors (N=173)
Variable N (%) Median duration (95% CI) Generalized log-rank test statistic
Overall 173 (100%) 9.3 (9.3, 11.5) –
CTa,c
 Negative 161 (93.1) 9.3 (9.3, 11.5)
p=0.05 Positive 11 (6.4) 19.4 (8.6, ∞)
 Missing 1 (0.6) –
GCa
 Negative 167 (96.5) 9.3 (9.3, 11.5)
p=0.16
 Positive 6 (3.5) 20.0 (5.0, ∞)
MGa
 Negative 157 (90.8) 10.3 (9.3, 11.3)
p=0.23
 Positive 16 (9.2) 7.8 (5.6, 12.1)
TVa
 Negative 144 (83.2) 9.3 (9.3, 11.5)
p=0.54
 Positive 29 (16.8) 10.2 (5.7, 19.4)
Cytological Resultsb
 Normal 131 (75.7) 7.9 (7.2, 12.1)
p=0.06 ASCUS/AGUS/LSIL 29 (16.8) 11.5 (10.2, ∞)
 HSIL 13 (7.51) 17.3 (11.0, 24.8)
HIV status
 Negative 122 (70.5) 11.4 (10.2, 11.5)
p=0.76
 Positive 51 (29.5) 9.3 (5.7, 23.6)
Age (years)
 18–24 54 (31.2) 9.4 (9.4, 11.5)
p=0.79
 25–29 57 (32.9) 11.5 (8.4, 17.2)
 30–34 32 (18.5) 10.7 (5.1, 10.8)
 35+ 30 (17.3) 9.6 (9.6, 16.1)
Duration of sex work
 More than 5 years 65 (37.6) 11.5 (9.3, 11.5)
p=0.13
 5 years or fewer 108 (62.4) 8.8 (5.9, 8.8)
Consistent condom use
 Half the time or less 50 (28.9) 9.6 (5.9, 17.3)
p=0.97 Most of the time 81 (46.8) 9.3 (9.1, 11.5)
 Always 42 (24.3) 13.2 (5.0, 17.3)
Average number of clients per week
 12 or more 86 (49.7) 11.2 (9.1, 17.2)
p=0.03
 Fewer than 12 87 (50.3) 9.3 (9.3, 10.3)
a
CT=chlamydia trachomatis; GC=neisseria gonorrhea; MG=mycoplasma genitalium; TV=trichomonas vaginalis; HIV=human immunodeficiency 
virus
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b
ASCUS=atypical squamous cells of undetermined significance; AGUS=atypical glandular cells of undetermined significance; LSIL=low-grade 
squamous intraepithelial lesions; HSIL=high-grade squamous intraepithelial lesions
c
Median time to clearance was unavailable if fewer than 50% in the stratum achieved clearance. Instead, the 25th percentile is used.
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Table 2
Crude and adjusted time ratios (TR)a for duration of (hrHPV) infection by baseline health status and sexual 
risk factors (N=173)
Variable N (%) Crude TR (95% CI) Adjusted TRe (95% CI)
CTc
 Negative 161 (93.1) 1.0 (ref) 1.0 (ref)
 Positive 11b (6.4) 1.9 (1.1, 3.1) 1.7 (1.2, 2.6)
GCc
 Negative 167 (96.5) 1.0 (ref)
 Positive 6 (3.5) 0.8 (0.5, 1.3)
TVc
 Negative 157 (90.8) 1.0 (ref)
 Positive 16 (9.2) 1.0 (0.7, 1.4)
MGc
 Negative 144 (83.2) 1.0 (ref)
 Positive 29 (16.8) 0.9 (0.7, 1.2)
Cytological Resultsd
 Normal 131 (75.7) 1.0 (ref) 1.0 (ref)
 ASCUS/AGUS/LSIL 29 (16.8) 1.6 (1.2, 2.3) 1.8 (1.5, 2.2)
 HSIL 13 (7.51) 2.2 (1.7, 2.9) 2.1 (1.6, 2.7)
HIV statusc
 Negative 122 (70.5) 1.0 (ref)
 Positive 51 (29.5) 0.8 (0.6, 1.0)
Age
 18–24 54 (31.2) 1.0 (ref)
 25–29 57 (32.9) 1.0 (0.8, 1.2)
 30–34 32 (18.5) 1.2 (0.6, 1.1)
 35+ 30 (17.3) 1.0 (0.8, 1.3)
Duration of sex work
 More than 5 years 65 (37.6) 1.0 (ref)
 5 years or fewer 108 (62.4) 0.8 (0.7, 1.0)
Consistent condom use
 Half the time or less 50 (28.9) 1.0 (ref)
 Most of the time 81 (46.8) 1.1 (0.8, 1.3)
 Always 42 (24.3) 0.9 (0.6, 1.2)
Average number of clients per week
 12 or more 86 (49.7) 1.0 (ref)
 Fewer than 12 87 (50.3) 1.0 (0.8, 1.2)
a
Time ratio reflects the relative duration of hrHPV infection, comparing those with a given characteristic to those without.
b
1 observation missing
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c
CT=chlamydia trachomatis; GC=neisseria gonorrhea; MG=mycoplasma genitalium; TV=trichomonas vaginalis; HIV=human immunodeficiency 
virus
d
ASCUS=atypical squamous cells of undetermined significance; AGUS=atypical glandular cells of undetermined significance; LSIL=low-grade 
squamous intraepithelial lesions; HSIL=high-grade squamous intraepithelial lesions
e
Adjusted for baseline HIV status and age
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